Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2355496 | 1.00 | DPP4 (0.46) | DPP4DPP7HDAC1HDAC8DPP9 | |
| SCHEMBL343719 | 1.00 | DPP4 (0.46) | DPP4DPP7HDAC1HDAC8DPP9 | |
| SCHEMBL29362057 | 1.00 | DPP4 (0.46) | DPP4DPP7HDAC1HDAC8DPP9 | |
| SCHEMBL7140778 | 0.81 | DPP4 (0.52) | DPP4DPP7 | |
| SCHEMBL10022727 | 0.81 | DPP4 (0.52) | DPP4DPP7 | |
| SCHEMBL1552897 | 0.81 | HTR2A (0.35) | DPP4 | |
| SCHEMBL1552901 | 0.81 | HTR2A (0.35) | DPP4 | |
| SCHEMBL1552994 | 0.79 | MEN1 (0.38) | DPP4DPP9 | |
| SCHEMBL1552997 | 0.79 | MEN1 (0.38) | DPP4DPP9 | |
| SCHEMBL20630900 | 0.78 | DPP4 (0.52) | DPP4DPP7DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113979853-A | Preparation method of (S) -3-hydroxy-4- (2,4, 5-trifluorophenyl) butyric acid | 上海科利生物医药有限公司 | 2022-01-28 | — | — | CN | claimed |
| EP-2491040-A2 | METHOD OF PREPARING SITAGLIPTIN AND INTERMEDIATES USED THEREIN | Hanmi Holdings Co., Ltd. (KR) | 2012-08-29 | — | — | EP | claimed |
| US-20120214997-A1 | METHOD OF PREPARING SITAGLIPTIN AND INTERMEDIATES USED THEREIN | HANMI HOLDINGS CO., LTD. (KR) | 2012-08-23 | — | — | US | claimed |
| EP-2397141-A1 | Process for the synthesis of beta-amino acids and derivatives thereof | LEK Pharmaceuticals d.d. (SI) | 2011-12-21 | — | — | EP | claimed |
| WO-2011049344-A2 | METHOD OF PREPARING SITAGLIPTIN AND INTERMEDIATES USED THEREIN | HANMI HOLDINGS CO., LTD. (KR) | 2011-04-28 | — | — | WO | claimed |
| CN-113979853-A | Preparation method of (S) -3-hydroxy-4- (2,4, 5-trifluorophenyl) butyric acid | 上海科利生物医药有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-9249109-B2 | Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2016-02-02 | — | — | US | disclosed |
| US-20150025241-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2015-01-22 | — | — | US | disclosed |
| EP-2415753-B1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG A PHARM CO LTD (KR) | 2014-08-27 | — | — | EP | disclosed |
| US-8624026-B2 | Method of preparing sitagliptin and intermediates used therein | HANMI SCIENCE CO., LTD (KR) | 2014-01-07 | — | — | US | disclosed |
| US-8624026-B2 | Method of preparing sitagliptin and intermediates used therein | HANMI SCIENCE CO., LTD (KR) | 2014-01-07 | — | — | US | disclosed |
| EP-2669265-A2 | Improved method for preparing dipeptidyl peptidase-IV inhibitor and intermediate | Dong-A Pharmaceutical Co., Ltd. (KR) | 2013-12-04 | — | — | EP | disclosed |
| EP-2415753-A2 | IMPROVED METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | Dong-A Pharmaceutical Co., Ltd. (KR) | 2012-02-08 | — | — | EP | disclosed |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| EP-2397141-A1 | Process for the synthesis of beta-amino acids and derivatives thereof | LEK Pharmaceuticals d.d. (SI) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397141-A1 | Process for the synthesis of beta-amino acids and derivatives thereof | LEK Pharmaceuticals d.d. (SI) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011102640-A2 | METHOD FOR PREPARING SITAGLIPTIN AND AMINE SALT INTERMEDIATES USED THEREIN | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011049344-A2 | METHOD OF PREPARING SITAGLIPTIN AND INTERMEDIATES USED THEREIN | HANMI HOLDINGS CO., LTD. (KR) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049344-A2 | METHOD OF PREPARING SITAGLIPTIN AND INTERMEDIATES USED THEREIN | HANMI HOLDINGS CO., LTD. (KR) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011040717-A2 | METHOD FOR PREPARING INTERMEDIATE OF SITAGLIPTIN USING CHIRAL OXIRANE | HANMI HOLDINGS CO., LTD. (KR) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025241-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885HDAC1 2233/4885 |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885HDAC1 2233/4885 |
| US-20120214997-A1 | METHOD OF PREPARING SITAGLIPTIN AND INTERMEDIATES USED THEREIN | DPP4, DPP7, DPP8 | DPP4 1/4885DPP7 2/4885HDAC1 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.